Physicians & Pharmacists

OUR MEDICINES

Santhera is passionate about medical science and about developing new medical treatments for patients with rare and other diseases. Our focus is on the development of therapies for rare neuromuscular and pulmonary conditions with high unmet medical needs.

Welcome!

Medical doctors who wish to learn more about our products and pipeline are invited to access the restricted physician section here.

Pharmacies seeking information about product availability and order placement are invited to access the pharmacist section here.

Our products and pipeline

Santhera has an exclusive license for all indications worldwide to AGAMREE® (vamorolone), a first-in-class dissociative steroid with a novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy as an alternative to standard corticosteroids. AGAMREE is approved for the treatment of DMD in the U.S., the EU and the UK. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases.